Yunmi Park


Yunmi Park
BS, Genetic Engineering
Kyung Hee University
Seoul, Korea
MS Student in Pharmacology & Drug Development
David Greenblatt, MD, Adviser




Zolpidem (Ambien) is a benzodiazepine agonist hypnotic drug that is extensively prescribed throughout the world. There are large individual differences in metabolic clearance (metabolism and biotransformation) of zolpidem which in turn may result in corresponding differences in clinical responses and adverse reactions among individuals receiving standard doses. My research is to uncover the basis for individual variation in zolpidem response and metabolism using an in vitro metabolic model derived from human liver microsomal preparations. I am trying to Identify demographic characteristics and mutations that contribute to various metabolic phenotypes present in the human liver microsomes.

Back to the Greenblatt Profile Page

Apply to the Sackler School


The priority application deadlines are as follows:

December 1: Basic Science Division PhD Programs

February 15: Building Diversity in Biomedical Sciences

March 31: Post-Baccalaureate Research Program

May 1: Clinical & Translational Science, MS in Pharmacology & Drug Development

June 15: Online Certificate in Fundamentals of Clinical Care Research